title: Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension.
abstract: The tolerability and hemodynamic and humoral effects of the structurally novel calcium antagonist Ro 40-5967 were investigated in 64 patients with hypertension. In a double-blind, placebo-controlled study, ascending oral doses of 50, 100, 150, or 200 mg were administered once daily for 8 days in a solution. Ro 40-5967 was well tolerated up to 150 mg, but treatment was stopped in one patient in the 200 mg group because of bradycardia. Blood pressure was dose-dependently reduced over the full 24-hour dosing period with more pronounced effects on day 8 than on day 1. The maximum blood pressure reduction was obtained after 150 mg (supine blood pressure, -34/-25 mm Hg, p less than 0.001). Despite a slight decrease in supine heart rate, cardiac output increased. PQ time was dose-dependently increased and concentration-effect analysis showed that relevant atrioventricular conduction disturbances occur only at concentrations much higher than those required to reduce blood pressure. Changes in catecholamines, plasma renin activity, and aldosterone were small and inconsistent. In conclusion, Ro 40-5967 has a long-lasting antihypertensive effect after once-daily administration.
authors.affiliation: F. Hoffmann-La Roche Ltd., Clinical Research and Development, Basel, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Schmitt
authors.forename: C H
authors.initials: CH
authors.lastname: Kleinbloesem
authors.forename: G G
authors.initials: GG
authors.lastname: Belz
authors.forename: V
authors.initials: V
authors.lastname: Schroeter
authors.forename: U
authors.initials: U
authors.lastname: Feifel
authors.forename: H
authors.initials: H
authors.lastname: Pozenel
authors.forename: W
authors.initials: W
authors.lastname: Kirch
authors.forename: A
authors.initials: A
authors.lastname: Halabi
authors.forename: A J
authors.initials: AJ
authors.lastname: Woittiez
authors.forename: H A
authors.initials: HA
authors.lastname: Welker
mesh_terms: D000450:Aldosterone / Q000097:blood; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002395:Catecholamines / Q000097:blood; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D020748:Mibefradil; D008875:Middle Aged; D010919:Placebos; D012083:Renin / Q000097:blood; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D002395:Catecholamines; D010919:Placebos; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D000450:Aldosterone; D012083:Renin